ADMA BIOLOGICS, INC. Proceeds from Long-Term Debt Issued
ADMA BIOLOGICS, INC. (ADMA) reported Proceeds from Long-Term Debt Issued of $0 for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2021-05-12
- ADMA BIOLOGICS, INC. proceeds from issuance of long-term debt for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- ADMA BIOLOGICS, INC. proceeds from issuance of long-term debt for the quarter ending 2020-12-31 was $15.00M.
- ADMA BIOLOGICS, INC. proceeds from issuance of long-term debt for the quarter ending 2020-09-30 was $0.00.
- ADMA BIOLOGICS, INC. proceeds from issuance of long-term debt for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- ADMA BIOLOGICS, INC. proceeds from issuance of long-term debt for fiscal 2020 was $27.50M, a 62.07% decline from fiscal 2019.
- ADMA BIOLOGICS, INC. proceeds from issuance of long-term debt for fiscal 2019 was $72.50M.
- ADMA BIOLOGICS, INC. proceeds from issuance of long-term debt for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- ADMA BIOLOGICS, INC. proceeds from issuance of long-term debt for fiscal 2017 was $30.00M, a 650.00% increase from fiscal 2016.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2021-03-31 | $0.00 10-Q · filed 2021-05-12 | $15.00M derived: sum of 2 quarters · filed 2021-05-12 | $15.00M derived: sum of 3 quarters · filed 2021-05-12 | $15.00M derived: sum of 4 quarters · filed 2021-05-12 |
| 2020-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $15.00M derived: sum of 2 quarters · filed 2021-03-25 | $15.00M derived: sum of 3 quarters · filed 2021-03-25 | $27.50M 10-K · filed 2021-03-25 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $12.50M 10-Q · filed 2020-11-05 | $12.50M derived: sum of 4 quarters · filed 2021-05-12 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $12.50M 10-Q · filed 2020-08-05 | $12.50M derived: sum of 3 quarters · filed 2021-05-12 | $12.50M derived: sum of 4 quarters · filed 2021-05-12 |
| 2020-03-31 | $12.50M 10-Q · filed 2021-05-12 | $12.50M derived: sum of 2 quarters · filed 2021-05-12 | $12.50M derived: sum of 3 quarters · filed 2021-05-12 | $40.00M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $27.50M derived: sum of 3 quarters · filed 2021-03-25 | $72.50M 10-K · filed 2021-03-25 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $27.50M derived: sum of 2 quarters · filed 2020-11-05 | $72.50M 10-Q · filed 2020-11-05 | $72.50M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $27.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $72.50M 10-Q · filed 2020-08-05 | $72.50M derived: sum of 3 quarters · filed 2020-08-05 | $72.50M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $45.00M 10-Q · filed 2020-05-06 | $45.00M derived: sum of 2 quarters · filed 2020-05-06 | $45.00M derived: sum of 3 quarters · filed 2020-05-06 | $45.00M derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $0.00 derived: sum of 2 quarters · filed 2020-03-13 | $0.00 derived: sum of 3 quarters · filed 2020-03-13 | $0.00 10-K · filed 2020-03-13 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $0.00 10-Q · filed 2019-11-06 | $30.00M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | $30.00M derived: sum of 3 quarters · filed 2019-08-08 | $30.00M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-08 | $30.00M derived: sum of 2 quarters · filed 2019-05-08 | $30.00M derived: sum of 3 quarters · filed 2019-05-08 | |
| 2017-12-31 | $30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $30.00M derived: sum of 2 quarters · filed 2019-03-13 | $30.00M 10-K · filed 2019-03-13 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $0.00 10-Q · filed 2017-11-03 | ||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-11 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $0.00 derived: sum of 2 quarters · filed 2018-03-29 | $4.00M 10-K · filed 2018-03-29 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $4.00M 10-Q · filed 2017-11-03 | ||
| 2016-06-30 | $4.00M 10-Q · filed 2017-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |